Compare Abeona Therapeutics Inc (ABEO) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Procter & Gamble Co — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Procter & Gamble Co trades at $148.5 (market cap $355.69B). The key difference: Procter & Gamble Co is far larger — about 952.8× Abeona Therapeutics Inc's market cap, and Procter & Gamble Co pays a 2.79% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PG | |
|---|---|---|
Market Cap | $373.32M | $355.69B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $167.18 |
52-Week Low | $4.17 | $138.10 |
Enterprise Value | $228.22M | $381.17B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Procter & Gamble (PG) trades at $152.75, up 2.3% recently, with a bullish technical signal and strong support near $151. The company reported consistent earnings beats, with Q1 2026 EPS of $1.59 exceeding the $1.56 estimate, and maintains robust profitability with a 19.16% net income margin. Recent developments include a new WNBA partnership and a $1.09 dividend payment scheduled for May 2026.
PG offers stable growth and income appeal, supported by a 55.77% analyst buy rating and a $159.88 consensus price target. Risks include premium valuation multiples and soft demand concerns. The stock's resilience in volatile markets positions it as a defensive holding, though margin pressures from inflation remain a watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
